Precision BioSciences (DTIL) Competitors $7.18 +0.02 (+0.28%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends DTIL vs. FRLN, CLLS, EDIT, TCRX, GNFT, MOLN, AMRN, SOPH, MGNX, and CRBPShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Freeline Therapeutics (FRLN), Cellectis (CLLS), Editas Medicine (EDIT), TScan Therapeutics (TCRX), Genfit (GNFT), Molecular Partners (MOLN), Amarin (AMRN), SOPHiA GENETICS (SOPH), MacroGenics (MGNX), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "medical" sector. Precision BioSciences vs. Freeline Therapeutics Cellectis Editas Medicine TScan Therapeutics Genfit Molecular Partners Amarin SOPHiA GENETICS MacroGenics Corbus Pharmaceuticals Precision BioSciences (NASDAQ:DTIL) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Does the media favor DTIL or FRLN? In the previous week, Precision BioSciences had 2 more articles in the media than Freeline Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 0 mentions for Freeline Therapeutics. Precision BioSciences' average media sentiment score of 0.00 equaled Freeline Therapeutics'average media sentiment score. Company Overall Sentiment Precision BioSciences Neutral Freeline Therapeutics Neutral Do analysts prefer DTIL or FRLN? Precision BioSciences presently has a consensus price target of $39.50, indicating a potential upside of 450.14%. Freeline Therapeutics has a consensus price target of $6.50, indicating a potential upside of 0.31%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Freeline Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Freeline Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in DTIL or FRLN? Precision BioSciences received 56 more outperform votes than Freeline Therapeutics when rated by MarketBeat users. Likewise, 67.67% of users gave Precision BioSciences an outperform vote while only 64.15% of users gave Freeline Therapeutics an outperform vote. CompanyUnderperformOutperformPrecision BioSciencesOutperform Votes9067.67% Underperform Votes4332.33% Freeline TherapeuticsOutperform Votes3464.15% Underperform Votes1935.85% Which has higher valuation and earnings, DTIL or FRLN? Precision BioSciences has higher revenue and earnings than Freeline Therapeutics. Freeline Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$48.73M1.13-$61.32M$0.06119.69Freeline TherapeuticsN/AN/A-$88.97M-$5.59-1.16 Is DTIL or FRLN more profitable? Precision BioSciences has a net margin of 11.48% compared to Freeline Therapeutics' net margin of 0.00%. Precision BioSciences' return on equity of -23.69% beat Freeline Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences11.48% -23.69% -6.98% Freeline Therapeutics N/A -150.46%-97.01% Which has more risk & volatility, DTIL or FRLN? Precision BioSciences has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Freeline Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Do institutionals and insiders believe in DTIL or FRLN? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 46.3% of Freeline Therapeutics shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by insiders. Comparatively, 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryPrecision BioSciences beats Freeline Therapeutics on 15 of the 16 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.07M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio119.6916.1687.8613.46Price / Sales1.13282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book0.854.436.946.30Net Income-$61.32M-$41.63M$119.12M$225.93M7 Day Performance-6.75%-4.73%-1.84%-1.32%1 Month Performance-18.59%-6.53%-3.65%0.60%1 Year Performance-42.98%25.63%31.64%26.23% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.0302 of 5 stars$7.18+0.3%$39.50+450.1%-46.6%$55.07M$48.73M119.69200Gap UpFRLNFreeline TherapeuticsN/A$6.48flat$6.50+0.3%N/A$28.12MN/A-1.16152CLLSCellectis2.4726 of 5 stars$1.91-2.6%$7.00+266.5%-38.4%$106.16M$9.19M0.00290Analyst ForecastEDITEditas Medicine4.6915 of 5 stars$2.44+1.2%$9.08+272.3%-77.8%$201.42M$78.12M-0.94230Short Interest ↓TCRXTScan Therapeutics2.9905 of 5 stars$4.12-2.1%$12.00+191.3%-10.6%$218.24M$21.05M0.00100GNFTGenfit1.4608 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$215.28M$41.31M0.00120MOLNMolecular Partners0.2312 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$209.76M$7.84M0.00180AMRNAmarin0.1111 of 5 stars$0.51+3.3%N/A-37.4%$209.65M$306.91M0.00360Negative NewsSOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$207.26M$62.37M0.00520MGNXMacroGenics3.8708 of 5 stars$3.28-5.7%$7.63+132.5%-57.0%$205.85M$58.75M0.00430CRBPCorbus Pharmaceuticals4.8781 of 5 stars$16.80+4.5%$65.86+292.0%+249.6%$204.62M$880,000.00-3.4340Positive News Related Companies and Tools Related Companies Freeline Therapeutics Alternatives Cellectis Alternatives Editas Medicine Alternatives TScan Therapeutics Alternatives Genfit Alternatives Molecular Partners Alternatives Amarin Alternatives SOPHiA GENETICS Alternatives MacroGenics Alternatives Corbus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DTIL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
